BidaskClub upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday.

MDSO has been the subject of a number of other research reports. Dougherty & Co restated a buy rating and set a $89.00 target price (up previously from $79.00) on shares of Medidata Solutions in a report on Thursday, May 10th. Royal Bank of Canada upgraded Medidata Solutions from a sector perform rating to an outperform rating and set a $100.00 target price for the company in a report on Tuesday, July 17th. Zacks Investment Research lowered Medidata Solutions from a hold rating to a sell rating in a report on Thursday, June 21st. JPMorgan Chase & Co. lowered Medidata Solutions from an overweight rating to a neutral rating and set a $87.00 target price for the company. in a report on Tuesday, July 24th. Finally, ValuEngine lowered Medidata Solutions from a buy rating to a hold rating in a report on Tuesday, July 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $86.93.

Medidata Solutions stock opened at $78.21 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.16. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of 92.01, a P/E/G ratio of 4.87 and a beta of 1.40. Medidata Solutions has a twelve month low of $59.60 and a twelve month high of $88.87.

Medidata Solutions (NASDAQ:MDSO) last posted its earnings results on Tuesday, July 24th. The company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $155.90 million during the quarter, compared to analyst estimates of $155.86 million. Medidata Solutions had a return on equity of 11.37% and a net margin of 9.13%. Medidata Solutions’s revenue was up 14.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.31 earnings per share. analysts anticipate that Medidata Solutions will post 0.79 earnings per share for the current fiscal year.

In other news, Director Robert Taylor sold 3,630 shares of the stock in a transaction on Monday, June 4th. The stock was sold at an average price of $78.70, for a total transaction of $285,681.00. Following the completion of the sale, the director now owns 49,036 shares in the company, valued at approximately $3,859,133.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Rouven Bergmann sold 3,000 shares of the stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $82.85, for a total value of $248,550.00. Following the sale, the chief financial officer now owns 81,642 shares of the company’s stock, valued at approximately $6,764,039.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,418 shares of company stock valued at $2,860,168. Company insiders own 4.70% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Medidata Solutions in the 4th quarter valued at $2,467,000. Joel Isaacson & Co. LLC acquired a new position in shares of Medidata Solutions in the 1st quarter valued at $314,000. Comerica Bank increased its position in shares of Medidata Solutions by 9.3% in the 1st quarter. Comerica Bank now owns 61,772 shares of the company’s stock valued at $4,537,000 after acquiring an additional 5,250 shares during the period. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Medidata Solutions in the 1st quarter valued at $26,769,000. Finally, Kornitzer Capital Management Inc. KS increased its position in shares of Medidata Solutions by 17.1% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 161,900 shares of the company’s stock valued at $10,169,000 after acquiring an additional 23,665 shares during the period.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Further Reading: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.